Cameron Williams, DO
Internal Medicine · Plymouth Meeting, PANPI 1902395957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.9% of the total. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$584
- Acadia Pharmaceuticals Inc$528
- Otsuka America Pharmaceutical, Inc.$462
- Sumitomo Pharma America, Inc.$250
- Neurocrine Biosciences, Inc.$139
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,90094%
- Education$2496%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,149 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 320 | $117,720 |
| RexultiBrexpiprazole | 75 | $40,140 |
| AustedoDeutetrabenazine | 21 | $28,369 |
| TrulicityDulaglutide | 34 | $27,409 |
| JanuviaSitagliptin Phosphate | 47 | $22,974 |
| OzempicSemaglutide | 19 | $19,624 |
| TradjentaLinagliptin | 68 | $18,457 |
| SantylCollagenase Clostridium Hist. | 22 | $16,058 |
| JardianceEmpagliflozin | 41 | $13,971 |
| GemtesaVibegron | 44 | $12,044 |
| LokelmaSodium Zirconium Cyclosilicate | 29 | $11,245 |
| Lacosamide | 89 | $11,017 |
| Divalproex Sodium | 191 | $10,987 |
| XareltoRivaroxaban | 20 | $10,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $10,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $117,720320 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $462 | $40,14075 claims |
| Boehringer IngelheimTradjenta, Jardiance | $23 | $32,428109 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,034 | $28,36921 claims |
| Lilly USA, LLCTrulicity | $112 | $27,40934 claims |
| MerckJanuvia | $15 | $22,97447 claims |
| GSKTrelegy Ellipta, Arexvy | $19 | $19,99348 claims |
| Novo NordiskOzempic | $36 | $19,62419 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $250 | $12,04444 claims |
| AstraZenecaLokelma | $584 | $11,24529 claims |
| Johnson & JohnsonXarelto | $19 | $10,74920 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $117 | $2,836251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Plymouth Meeting
- Andrew GrafPlymouth Meeting$170K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.